治疗与 RPGR 基因变异相关的 X 连锁视网膜色素变性的基因治疗试验
AAV5-RPGR 治疗与 RPGR 基因变异相关的 X 连锁视网膜色素变性的第 3 期随机对照研究
A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Glostrup Municipality、丹麦、2600
- Rigshospitalet Glostrup
-
-
-
-
-
Jerusalem、以色列、91120
- Hadassah Medical Center
-
-
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- Hospital For Sick Children
-
-
-
-
-
Florence、意大利、50134
- Azienda Ospedaliero Universitaria Careggi
-
Milan、意大利、20142
- Ospedale San Paolo
-
Naples、意大利、80131
- Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli
-
Roma、意大利、00198
- IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS
-
-
-
-
-
Ghent、比利时、9000
- UZ Gent
-
-
-
-
-
Paris、法国、75012
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
-
-
-
-
-
Basel、瑞士、4031
- University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical
-
Lausanne、瑞士、1004
- Universite de Lausanne, Hopital ophtalmique Jules-Gonin
-
-
-
-
California
-
La Jolla、California、美国、92093 0946
- Shiley Eye Institute Jacobs Retina Center
-
Los Angeles、California、美国、90027
- Childrens Hospital
-
Palo Alto、California、美国、94303
- Stanford Health Care
-
-
Florida
-
Gainesville、Florida、美国、32607
- VitreoRetinal Associates, PA
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Emory University
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital - Center for Celiac Research and Treatment
-
-
Michigan
-
Ann Arbor、Michigan、美国、48105
- Univ of Michigan Medical Center
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- Duke Eye Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh Medical Center (UPMC)
-
-
Texas
-
Bellaire、Texas、美国、77401
- Retina Consultants of Houston
-
-
-
-
-
Edinburgh、英国、EH3 9HA
- NHS Lothian
-
Glasgow、英国、G12 0YN
- Gartnavel General Hospital
-
Leeds、英国、LS9 7TF
- St James University Hospital
-
London、英国、EC1V 2PD
- Moorfields Eye Hospital
-
-
-
-
-
Amsterdam、荷兰、1105AZ
- VUMC Amsterdam
-
Nijmegen、荷兰、6525EX
- Radboudumc
-
-
-
-
-
Madrid、西班牙、28040
- Hosp Univ Fund Jimenez Diaz
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female
- 3 years of age or older
- Has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory
Exclusion Criteria:
- Has had ocular surgery within 3 months prior to screening or is anticipated to require ocular surgery within 6 months after the study intervention administration
- Any investigational ocular treatment or any other ocular treatment that could confound the interpretation of the efficacy results or affect participant compliance with the visit schedule
- Has undergone prior retinal surgery involving the macula, macular laser photocoagulation, external-beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental - Immediate Treatment
Intermediate dose. |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
其他名称:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
|
其他:Deferred Treatment
Deferred Treatment |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
其他名称:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
|
实验性的:Experimental Immediate Treatment
Low dose. |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
其他名称:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline to Week 52 in Vision-guided Mobility Assessment (VMA) as Measured by the Ability of the Participant to Navigate Through a VMA Maze
大体时间:From Baseline to 52 Weeks
|
Change from baseline to Week 52 in VMA as measured by the ability of the participant to navigate through a VMA maze. |
From Baseline to 52 Weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in Mean Retinal Sensitivity Within the Central 10 Degrees Excluding Scotoma (Mean Retinal Sensitivity Within the Central 10 Degree Excluding Scotoma in Static Perimetry [MRS10]) in Static Perimetry at Week 52
大体时间:From Baseline to Week 52
|
Change from baseline in mean retinal sensitivity within the central 10 degrees excluding scotoma (MRS10) in static perimetry at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change From Baseline in Mean Retinal Sensitivity of Worse-seeing Eye Within the Central 10 Degrees Excluding Scotoma in Static Perimetry (MRS10) at Week 52
大体时间:From Baseline to Week 52
|
Change from baseline in mean retinal sensitivity of worse-seeing eye within the central 10 degrees excluding scotoma in static perimetry (MRS10) at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Full Visual Field at Week 52
大体时间:From Baseline to Week 52
|
Pointwise response in full visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in Full Visual Field at Week 52
大体时间:From Baseline to Week 52
|
Pointwise response in worse-seeing eye in full visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in the Central 30 Degrees Visual Field at Week 52
大体时间:From Baseline to Week 52
|
Pointwise response in the central 30 degrees visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in the Central 30 Degrees Visual Field at Week 52
大体时间:From Baseline to Week 52
|
Pointwise response in worse-seeing eye in the central 30 degrees visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change From Baseline in Retinal Function as Assessed by Mean Retinal Sensitivity Within the Full Visual Field (MRS90) in Static Perimetry at Week 52
大体时间:From Baseline to Week 52
|
Change from baseline in retinal function as assessed by mean retinal sensitivity within the full visual field (MRS90) in static perimetry at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Functional Vision by Using Vision-guided Mobility Assessment (VMA) Response in the "Worse-seeing Eye" at Week 52
大体时间:From Baseline to Week 52
|
Change in functional vision by using VMA assessment in the "Worse-seeing Eye" at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52
大体时间:From Baseline to Week 52
|
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by Monocular Low Luminance Visual Acuity Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter score at Week 52
大体时间:From Baseline to Week 52
|
Change from baseline in visual function as assessed by monocular low luminance visual acuity using the ETDRS chart letter score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by monocular Best Corrected Visual Acuity (BCVA) Using the ETDRS Chart Letter Score at Week 52
大体时间:From Baseline to Week 52
|
Change From Baseline in visual function as assessed by monocular BCVA using the ETDRS chart letter score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by Low Luminance Visual Acuity Using the ETDRS Chart Letter Score in Worse-seeing Eye at Week 52
大体时间:From Baseline to Week 52
|
Change from baseline in visual function as assessed by low luminance visual acuity using the ETDRS chart letter score in worse-seeing eye at Week 52. |
From Baseline to Week 52
|
|
Number of Participants with Ocular and Non-ocular Adverse Events
大体时间:Day 1 - Week 52
|
Number of participants with ocular and non-ocular adverse events will be assessed. |
Day 1 - Week 52
|
|
Number of Participants With Abnormalities in Laboratory Assessments
大体时间:Day 1 - 52 Weeks
|
Number of participants with abnormalities in laboratory assessments will be assessed. |
Day 1 - 52 Weeks
|
合作者和调查者
调查人员
- 研究主任:Study Director、MeiraGTx Ocular UK Ltd
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CR109258
- 2020-002873-88 (EudraCT编号)
- MGT-RPGR-021 (其他标识符:MeiraGTx Ocular UK Ltd)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.